Recursion Pharmaceuticals, Inc. (RXRX) vs First Tracks Biotherapeutics, Inc. (TRAX)

Recursion Pharmaceuticals, Inc. and First Tracks Biotherapeutics, Inc. are both Biotechnology companies. Recursion Pharmaceuticals, Inc. and First Tracks Biotherapeutics, Inc. are of similar size ($2.2B and $2.2B). First Tracks Biotherapeutics, Inc. has the higher net margin (0.00% vs −697.1%) and the higher return on invested capital (0.00% vs −88.5%). Across the 11 metrics below, First Tracks Biotherapeutics, Inc. leads on 10 and Recursion Pharmaceuticals, Inc. on 1.

Valuation

Metric RXRX TRAX Biotechnology median
P/E n/m n/m 11.58
P/S 28.41 n/m 9.61
P/B 2.14 11.90 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 20.26 n/m 9.43
Earnings yield (25.19%) (10.29%) (32.28%)
Free cash flow yield (16.22%) (6.25%) (22.27%)

Profitability

Metric RXRX TRAX Biotechnology median
Gross margin 29.21% — 68.81%
Operating margin (725.44%) 0.00% 0.00%
Net margin (697.13%) 0.00% 0.00%
Free cash flow margin (460.89%) 0.00% 0.00%
Return on equity (48.72%) 0.00% (50.30%)
Return on assets (36.29%) 0.00% (45.47%)
Return on invested capital (88.54%) 0.00% 0.00%

Growth

Metric RXRX TRAX Biotechnology median
Revenue growth (TTM) 56.18% — 6.78%
EPS growth (last fiscal year) 14.79% — 29.88%
Revenue growth, 5-year CAGR 79.91% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric RXRX TRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.01 9.16 4.74
Net debt to EBITDA 1.31 — 1.01

Dividend

Metric RXRX TRAX Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric RXRX TRAX Biotechnology median
Market cap 2.21b 2.20b 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack